FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Zhan Hangjun					2. Iss	2. Issuer Name and Ticker or Trading Symbol Kindred Biosciences, Inc. [KIN]									k all ap	plicable)	g Person(s) to		
(Last)	`	•	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/22/2019									Director Officer (give title below) Chief Scier		10% Owner Other (specify below) tific Officer		
C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	6. Individual or Joint/Group Filing (Check Applicable				
(Street) BURLINGAME CA 94010															Form	Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(Si	tate) ((Zip)																
			le I - N	Non-Deriv					1	Dis					_	1			
1. Title of Security (Instr. 3)				2. Transac Date (Month/Da		Year) Exec		ned n Date, Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (Disposed Of (D) (Instr. and 5)		3, 4 Secu Bene Owne		ficially d	5. Ownership Form: Direct D) or ndirect (I)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amoun	t (A)	or I	Price			(Instr. 4)	(Instr. 4)	
Common Stock					019				М		6,25	50	A	(1)	39	9,397(2)	D		
Common Stock 01/22/									F		2,30:	_	-	\$10.12			D		
Common Stock				01/23/2					F		2,132					34,960	D		
		Та	able II	- Derivation (e.g., p					uired, Di , options						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transac Code (II 8)		of Der Sec Acc (A) Dis of (nber ivative urities quired or posed	6. Date Exe Expiration (Month/Day	Date		7. Title and Amount of Securities Underlying Derivative Security (Ins and 4)		of De Se (In	. Price f erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
						v	(A)		Date Exercisable		piration te	Title	Amou or Numb of Share	ıber					
Restricted Stock Units	(1)	01/22/2019			M			6,250	(4)		(4)	Common Stock	6,2	50	\$0	18,750	D		

Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. Includes 2,000 shares acquired under the Kindred Biosciences, Inc. 2014 Employee Stock Purchase Plan (the "ESPP") on May 31, 2018 and 2,000 shares acquired under the ESPP on November 30, 2018.
- 3. These shares are being surrendered to satisfy a tax withholding obligation of the reporting person.
- 4. On January 22, 2018, the reporting person was granted 25,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

<u>/s/ Hangjun Zhan</u> <u>01/24/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.